KSC · 326030.KS
SK Biopharmaceuticals Co., Ltd.
₩77,900+₩100 (+0.13%)
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.94% below the high.
Loading market information…
KOE · 141080.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 05:25 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
LigaChem Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
LigaChem Biosciences Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -₩562. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow LigaChem Biosciences Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LigaChem Biosciences, Inc. specializes in the development and manufacturing of a broad spectrum of medical solutions, encompassing pharmaceuticals, medical devices, and essential healthcare supplies. Their extensive product offerings include various therapeutic agents such as antibiotics, anti-coagulants, and oncology treatments, alongside cutting-edge antibody-drug conjugates and protein-drug conjugates. Established on May 2, 2006, the company's headquarters are situated in Daejeon, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | ₩730+6.0% vs estimate | ₩51.58B0.0% vs estimate |
|---|
| Q4 2024 | Feb 14, 2025 | -₩149-120.43% vs estimate | ₩33.7B-34.66% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | ₩330+209.6% vs estimate | ₩30.42B-2.56% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩77,900+₩100 (+0.13%)
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.94% below the high.
₩39,100-₩1,900 (-4.63%)
ABL Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.82% below the high.
₩92,200-₩5,000 (-5.14%)
Peptron, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.48% below the high.
₩106,800-₩8,400 (-7.29%)
Voronoi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.56% below the high.
₩40,800-₩900 (-2.16%)
D&D Pharmatech’s quoted price sits in the lower half of its reported 52-week range, 65.01% below the high.
₩15,100+₩200 (+1.34%)
Daewoong Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.65% below the high.
₩5,385-₩285 (-5.03%)
Hyundai Bioscience Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 74.95% below the high.
₩18,560-₩1,050 (-5.35%)
AbClon Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.62% below the high.
